Nanoemulsion strategy of pioglitazone for the treatment of skin inflammatory diseases

Publication date: Available online 18 April 2019Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Lupe C. Espinoza, Marcelle Silva-Abreu, Ana C. Calpena, María J. Rodríguez-Lagunas, María-José Fábrega, María L. Garduño-Ramírez, Beatriz ClaresAbstractPioglitazone (PGZ) is a peroxisome proliferator-activated receptor agonist. Its role in the inflammatory response modulation opens the door for additional therapeutic applications. The purpose of this study was to develop a pioglitazone nanoemulsion (PGZ-NE) to investigate its anti-inflammatory efficacy on the skin. For that a NE vehicle aimed for skin delivery was optimized and characterized. The resulting PGZ-NE showed a good anti-inflammatory efficacy by decreasing the expression of adipose inflammatory cytokines IL-6, IL-1β and TNF-α. The properties of the developed nanocarrier allowed achieving a high permeation flux of PGZ through the skin as well as high retained amount in the skin, probably due to the depot effect of ingredients, which assured a prolonged local action, with good skin tolerability among participating individuals. Consequently, these results suggest that PGZ-NE may be used as an alternative treatment for inflammatory skin diseases such as rosacea, atopic dermatitis or psoriasis.Graphical abstractThe reported anti-inflammatory efficacy of pioglitazone, a peroxisome proliferator-activated receptor agonist was exploited for the elaboration of a therapeutic agent aimed for the treatm...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research